{
    "Trade/Device Name(s)": [
        "Panther Fusion SARS-CoV-2/Flu A/B/RSV assay"
    ],
    "Submitter Information": "Hologic, Inc.",
    "510(k) Number": "K242465",
    "Predicate Device Reference 510(k) Number(s)": [
        "K241240"
    ],
    "Regulatory Class": "Class II",
    "Product Code(s)": [
        "QOF",
        "OOI"
    ],
    "Summary Letter Date": "August 19, 2024",
    "Summary Letter Received Date": "August 20, 2024",
    "Submission Date": "October 15, 2024",
    "Regulation Number(s)": [
        "21 CFR 866.3981"
    ],
    "Regulation Name(s)": [
        "Device To Detect And Identify Nucleic Acid Targets In Respiratory Specimens From Microbial Agents That Cause The SARS-Cov-2 Respiratory Infection And Other Microbial Agents When In A Multi-Target Test"
    ],
    "Analyte Class(es)": [
        "virology"
    ],
    "Analyte(s)": [
        "SARS-CoV-2",
        "Influenza A Virus",
        "Influenza B Virus",
        "Respiratory Syncytial Virus (RSV)"
    ],
    "Specimen Type(s)": [
        "Nasopharyngeal swab",
        "Anterior nasal swab"
    ],
    "Specimen Container(s)": [
        "Viral Transport Medium (VTM)",
        "Universal Transport Medium (UTM)",
        "Enhanced Specimen Transport Medium (eSTM)"
    ],
    "Instrument(s)/Platform(s)": [
        "Panther Fusion System"
    ],
    "Method(s)/Technology(ies)": [
        "Multiplex real-time polymerase chain reaction (RT-PCR)",
        "Reverse transcriptase PCR",
        "Nucleic acid capture and elution"
    ],
    "Methodologies": [
        "Multiplex RT-PCR",
        "Qualitative detection",
        "Automated molecular testing"
    ],
    "Submission Type(s)": [
        "Assay",
        "Test"
    ],
    "Document Summary": "FDA 510(k) summary for Panther Fusion SARS-CoV-2/Flu A/B/RSV assay, a multiplex RT-PCR test for qualitative detection and differentiation of SARS-CoV-2, influenza A/B, and RSV from NP/AN swabs",
    "Indications for Use Summary": "A fully automated multiplexed RT-PCR test for qualitative detection and differentiation of SARS-CoV-2, influenza A, influenza B, and RSV nucleic acids from nasopharyngeal and anterior nasal swabs in individuals exhibiting signs and symptoms of respiratory tract infection, used on the Panther Fusion system",
    "fda_folder": "Microbiology"
}